Vir Biotechnology Inc [VIR] stock prices are up 5.23% to $6.44 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The VIR shares have gain 17.09% over the last week, with a monthly amount glided 4.04%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vir Biotechnology Inc [NASDAQ: VIR] stock has seen the most recent analyst activity on September 03, 2025, when Evercore ISI initiated its Outperform rating and assigned the stock a price target of $12. Previously, BofA Securities upgraded its rating to Buy on August 27, 2025, and kept the price target unchanged to $14. On January 29, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $9 on the stock. BofA Securities downgraded its rating to a Neutral and decreased its price target to $14 on September 08, 2023. JP Morgan upgraded its rating to an Overweight and reduced its price target to $34 on March 06, 2023. Goldman upgraded its rating to Buy for this stock on February 21, 2023, and upped its price target to $53. In a note dated January 27, 2023, Morgan Stanley upgraded an Equal-Weight rating on this stock and boosted its target price from $18 to $30.
The stock price of Vir Biotechnology Inc [VIR] has been fluctuating between $4.16 and $14.45 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Vir Biotechnology Inc [NASDAQ: VIR] shares were valued at $6.44 at the most recent close of the market. An investor can expect a potential return of 86.34% based on the average VIR price forecast.
Analyzing the VIR fundamentals
The Vir Biotechnology Inc [NASDAQ:VIR] reported sales of 16.86M for trailing twelve months, representing a drop of -89.92%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -35.62%, Pretax Profit Margin comes in at -33.0%, and Net Profit Margin reading is -33.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.5 and Total Capital is -0.55. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.17 points at the first support level, and at 5.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.66, and for the 2nd resistance point, it is at 6.88.
Ratios To Look Out For
It’s worth pointing out that Vir Biotechnology Inc [NASDAQ:VIR]’s Current Ratio is 7.25. Further, the Quick Ratio stands at 7.25, while the Cash Ratio is 2.85. Considering the valuation of this stock, the price to sales ratio is 53.14, the price to book ratio is 1.12.
Transactions by insiders
Recent insider trading involved SVF Endurance (Cayman) Limited, 10% Owner, that happened on Nov 25 ’25 when 1.25 million shares were purchased. EVP & Chief Financial Officer, O’Byrne Jason completed a deal on Nov 17 ’25 to sell 6799.0 shares. Meanwhile, Officer O’Byrne Jason bought 6799.0 shares on Nov 17 ’25.
